Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: a systematic review

With upcoming new treatment modalities for HER2-amplified breast cancer, the stratification of patients who will benefit from such agents is increasingly important. The promising antibody-drug conjugate trastuzumab-deruxtecan, which received accelerated FDA-approval in metastatic breast cancer based on the DESTINY-Breast01 trial, is an example of a novel effective HER2-targeted agent [1]. According to current ASCO-CAP guidelines HER2 is assessed by immunohistochemistry (IHC), complemented by (fluorescence) in situ hybridization (ISH) in case of equivocal (2+) results.

Source: Cancer Treatment Reviews - March 28, 2022 Category: Cancer & Oncology Authors: Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens Source Type: research